India university creates low-cost insulin pump: commercial partners wanted

Amrita University in southern India has developed what it bills as a low-cost insulin pump about one-tenth as expensive as imported alternatives. The university is also apparently talking to two "biomedical devices" companies about producing it commercially, though the school hasn't disclosed any names, according to The Hindu Business Line. Larger insulin pump makers like Medtronic ($MDT) may want to take note. With India's emerging market of 1 billion-plus people, we've long known that there are enormous opportunities there for life sciences companies, and either one of the parties in negotiations could be a major player. But the article also emphases the goal of developing a product that is much cheaper than "imported pumps," and a local enterprise based in India could easily win out in producing the cell-phone sized insulin delivery system. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.